On September 11, 2025, MIRA Pharmaceuticals, Inc. held its annual meeting, approving major changes including increasing shares in their incentive plan from 5 million to 8 million and the acquisition of SKNY Pharmaceuticals, which will bring in $5 million to MIRA. A total of 10,588,211 shares, or 55.52% of outstanding shares, were voted, with all proposals passing, reflecting strong shareholder support.